Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome

Summary.  Background: About 30% of patients with an episode of adequately treated deep venous thrombosis (DVT) develop the postthrombotic syndrome (PTS) within 2 years. During treatment with vitamin K antagonists (VKA) patients spend only 60% of time between an International Normalized Ratio (INR) of 2.0 and 3.0. We hypothesized that patients who spend a large amount of their time beneath this range will have an increased risk of the PTS. Objective: To investigate the relation between the quality of anticoagulant therapy with VKA and the risk of the development of the PTS. Methods: The time spent beneath the therapeutic range was calculated for patients with a first episode of DVT, who were treated with VKA for at least 3 months. At follow‐up assessments for a maximum of 5 years, presence and severity of signs and symptoms of PTS were recorded. Results: A total of 244 patients, with a median duration of follow‐up of 4.9 years were included for analysis. Of these, 81 patients (33%) developed the PTS. The multivariate model showed that patients who spend more than 50% of their time beneath an INR level of 2.0 are at higher risk for PTS [odds ratio (OR): 2.71, 95% CI: 1.44–5.10]. Conclusions: Low quality treatment with VKA, which is a common condition, is related to the occurrence of the PTS in patients with DVT. Strategies aimed at improving the quality of long‐term anticoagulation might have the potential to reduce the incidence of this complication.

[1]  B. Hutten,et al.  The relationship between adherence and quality of treatment with vitamin K antagonists , 2004, Journal of thrombosis and haemostasis : JTH.

[2]  W. Ageno,et al.  Body mass index is associated with the development of the post-thrombotic syndrome. , 2003, Thrombosis and haemostasis.

[3]  W. Ageno,et al.  Body mass index is associated with the development of the post-thrombotic syndrome , 2003, Thrombosis and Haemostasis.

[4]  E. Minar,et al.  Post-thrombotic syndrome after primary event of deep venous thrombosis 10 to 20 years ago. , 2001, Thrombosis research.

[5]  M. Prins,et al.  Comparison of Three Methods to Assess Therapeutic Quality Control of Treatment with Vitamin K Antagonists , 1999, Thrombosis and Haemostasis.

[6]  M. Prins,et al.  Long-Term Treatment of Venous Thromboembolic Disease , 1999, Thrombosis and Haemostasis.

[7]  E. Taioli,et al.  The Post-thrombotic Syndrome in Young Women: Retrospective Evaluation of Prognostic Factors , 1998, Thrombosis and Haemostasis.

[8]  M. Prins,et al.  Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. , 1997, The New England journal of medicine.

[9]  H. Büller,et al.  Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis , 1997, The Lancet.

[10]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[11]  P. Bossuyt,et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.

[12]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[13]  Immelman Ej,et al.  The postphlebitic syndrome. Pathophysiology, prevention and management. , 1984 .

[14]  E. Immelman,et al.  The postphlebitic syndrome. Pathophysiology, prevention and management. , 1984, Clinics in chest medicine.

[15]  D. Strandness,et al.  Long-term sequelae of acute venous thrombosis. , 1983, JAMA.